These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 34872104)
1. A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Ng SWK; Murphy T; King I; Zhang T; Mah M; Lu Z; Stickle N; Ibrahimova N; Arruda A; Mitchell A; Mai M; He R; Madala BS; Viswanatha DS; Dick JE; Chan S; Virtanen C; Minden MD; Mercer T; Stockley T; Wang JCY Blood Adv; 2022 Feb; 6(3):1064-1073. PubMed ID: 34872104 [TBL] [Abstract][Full Text] [Related]
2. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Ng SW; Mitchell A; Kennedy JA; Chen WC; McLeod J; Ibrahimova N; Arruda A; Popescu A; Gupta V; Schimmer AD; Schuh AC; Yee KW; Bullinger L; Herold T; Görlich D; Büchner T; Hiddemann W; Berdel WE; Wörmann B; Cheok M; Preudhomme C; Dombret H; Metzeler K; Buske C; Löwenberg B; Valk PJ; Zandstra PW; Minden MD; Dick JE; Wang JC Nature; 2016 Dec; 540(7633):433-437. PubMed ID: 27926740 [TBL] [Abstract][Full Text] [Related]
3. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916 [TBL] [Abstract][Full Text] [Related]
4. The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. Kim DDH; Novitzky Basso I; Kim TS; Yi SY; Kim KH; Murphy T; Chan S; Minden M; Pasic I; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Ng SWK; Stockley T; Zhang T; King I; Mattsson J; Wang JCY EJHaem; 2022 Aug; 3(3):873-884. PubMed ID: 36051057 [TBL] [Abstract][Full Text] [Related]
5. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Huang BJ; Smith JL; Farrar JE; Wang YC; Umeda M; Ries RE; Leonti AR; Crowgey E; Furlan SN; Tarlock K; Armendariz M; Liu Y; Shaw TI; Wei L; Gerbing RB; Cooper TM; Gamis AS; Aplenc R; Kolb EA; Rubnitz J; Ma J; Klco JM; Ma X; Alonzo TA; Triche T; Meshinchi S Nat Commun; 2022 Sep; 13(1):5487. PubMed ID: 36123353 [TBL] [Abstract][Full Text] [Related]
6. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505 [TBL] [Abstract][Full Text] [Related]
8. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients. Almohsen F; Al-Mudallal SS Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833 [TBL] [Abstract][Full Text] [Related]
9. A Novel 85-Gene Expression Signature Predicts Unfavorable Prognosis in Acute Myeloid Leukemia. Lai Y; Sheng L; Wang J; Zhou M; OuYang G Technol Cancer Res Treat; 2021; 20():15330338211004933. PubMed ID: 33784904 [TBL] [Abstract][Full Text] [Related]
10. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328 [TBL] [Abstract][Full Text] [Related]
11. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Bottomly D; Long N; Schultz AR; Kurtz SE; Tognon CE; Johnson K; Abel M; Agarwal A; Avaylon S; Benton E; Blucher A; Borate U; Braun TP; Brown J; Bryant J; Burke R; Carlos A; Chang BH; Cho HJ; Christy S; Coblentz C; Cohen AM; d'Almeida A; Cook R; Danilov A; Dao KT; Degnin M; Dibb J; Eide CA; English I; Hagler S; Harrelson H; Henson R; Ho H; Joshi SK; Junio B; Kaempf A; Kosaka Y; Laderas T; Lawhead M; Lee H; Leonard JT; Lin C; Lind EF; Liu SQ; Lo P; Loriaux MM; Luty S; Maxson JE; Macey T; Martinez J; Minnier J; Monteblanco A; Mori M; Morrow Q; Nelson D; Ramsdill J; Rofelty A; Rogers A; Romine KA; Ryabinin P; Saultz JN; Sampson DA; Savage SL; Schuff R; Searles R; Smith RL; Spurgeon SE; Sweeney T; Swords RT; Thapa A; Thiel-Klare K; Traer E; Wagner J; Wilmot B; Wolf J; Wu G; Yates A; Zhang H; Cogle CR; Collins RH; Deininger MW; Hourigan CS; Jordan CT; Lin TL; Martinez ME; Pallapati RR; Pollyea DA; Pomicter AD; Watts JM; Weir SJ; Druker BJ; McWeeney SK; Tyner JW Cancer Cell; 2022 Aug; 40(8):850-864.e9. PubMed ID: 35868306 [TBL] [Abstract][Full Text] [Related]
12. Cellular abundance-based prognostic model associated with deregulated gene expression of leukemic stem cells in acute myeloid leukemia. Han DJ; Kim S; Lee SY; Kang SJ; Moon Y; Kim HS; Kim M; Kim TM Front Cell Dev Biol; 2024; 12():1345660. PubMed ID: 38523628 [No Abstract] [Full Text] [Related]
14. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165 [TBL] [Abstract][Full Text] [Related]
15. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955 [TBL] [Abstract][Full Text] [Related]
17. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML. Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055 [TBL] [Abstract][Full Text] [Related]
18. Stem cell gene expression programs influence clinical outcome in human leukemia. Eppert K; Takenaka K; Lechman ER; Waldron L; Nilsson B; van Galen P; Metzeler KH; Poeppl A; Ling V; Beyene J; Canty AJ; Danska JS; Bohlander SK; Buske C; Minden MD; Golub TR; Jurisica I; Ebert BL; Dick JE Nat Med; 2011 Aug; 17(9):1086-93. PubMed ID: 21873988 [TBL] [Abstract][Full Text] [Related]
19. Identification of biomarkers for acute leukemia via machine learning-based stemness index. Zhang Y; Liu D; Li F; Zhao Z; Liu X; Gao D; Zhang Y; Li H Gene; 2021 Dec; 804():145903. PubMed ID: 34411647 [TBL] [Abstract][Full Text] [Related]
20. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia. Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]